With the second half of the year underway, Oppenheimer is highlighting what it calls its top small- and midcap seasonal standout investment ideas.
On the basis of price charts alone, Oppenheimer tapped midcap growth stocks as its top rotation idea from a technical perspective.
Oppenheimer has a $20 price target on Zeta, implying 18% upside from Tuesday's close.
In a note last month, RBC Capital Markets also rated Zeta outperform with a price target of $20.
In this area, Oppenheimer likes Viking Therapeutics , reiterating the stock as one of its best ideas.
Persons:
Oppenheimer, Russell, Brian Schwartz, Zeta, Novo Nordisk's Wegovy, Eli Lilly's Zepbound, Jay Olson, Freshpet
Organizations:
Oppenheimer, Zeta Global Holdings, Zeta, RBC Capital Markets, Novo Nordisk's, Viking Therapeutics, Therapeutics
Locations:
Zeta, Novo